2025-522381-68-00招募中4 期
Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- HRQoL will be evaluated with the EORTC QLQ-C30 questionnaire.
研究概览
简要总结
Health related quality of life
入排标准
- 年龄范围
- 18 years 至 65+ years(65+ Years, 18-64 Years)
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥18 years) with severe cancer refractory pain (all types of cancer), who have been receiving treatment with opioids for at least 4 weeks, and are expected to remain on opioids for the entire duration of the study. More than one opioid rotation has to be done before defining pain refractoriness.
- •Intrathecal therapy is recommended because of inefficacy or intolerance to strong systemic opioid treatment. Inefficacy is defined as mean daily visual analogue scale (VAS) pain inten-sity score at rest of ≥ 50 mm. Intolerance is defined as the occurrence of (severe) adverse events (AE) (even with dosage less than 200 mg/day of oral morphine equivalents) which prevents a further increase in the opioid dosage to obtain pain relief.
- •Patients suitable for IDD and with the ability to comply with the medical protocol and visits.
- •Survival prognosis of ≥ 3 months.
排除标准
- •Patients with active, severe infection.
- •Patients with known brain metastases.
- •Patients with high risk of hemorrhaging.
- •Patients with allergies for medication or IDD hardware.
- •Pregnant or lactating women.
- •Women who plan to become pregnant within 1 month after the study.
研究组 & 干预措施
MORPHINE HCl STEROP 10mg/1ml Oplossing voor injectie
Test
干预措施: MORPHINE HCl STEROP 10mg/1ml Oplossing voor injectie (Drug)
Ropivacaïne Fresenius Kabi 5 mg/ml oplossing voor injectie
Test
干预措施: Ropivacaïne Fresenius Kabi 5 mg/ml oplossing voor injectie (Drug)
MORPHINE HCl STEROP 40mg/1ml Oplossing voor injectie
Test
干预措施: MORPHINE HCl STEROP 40mg/1ml Oplossing voor injectie (Drug)
MARCAINE 0,5%, oplossing voor injectie
Test
干预措施: MARCAINE 0,5%, oplossing voor injectie (Drug)
Prialt 25 micrograms/ml solution for infusion
Test
干预措施: Prialt 25 micrograms/ml solution for infusion (Drug)
结局指标
主要结局
HRQoL will be evaluated with the EORTC QLQ-C30 questionnaire.
HRQoL will be evaluated with the EORTC QLQ-C30 questionnaire.
次要结局
- Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental, and social dimension.
- The survival rate in both groups, CMM and IDD, will be determined by recording the time from treatment initiation until death.
- Pain intensity will be measured with the VAS (ranging from 0 (no pain) to 100 (maximal pain)) in electronic format.
- Perceived stress will be assessed by using the 10-item Perceived Stress Scale (PSS; Cohen, Kamarch, & Mermelstein, 1983).
- Patient anxiety will be provided through the State Trait Anxiety Inventory (STAI).
- Using the Injustice Experience Questionnaire (IEQ), perceived injustice related to current health status will be assessed.
- The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy.
- To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed.
- Expenditures related to in-hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted each month after treatment initiation. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, AEs, changes in medication (daily morphine or MED), or incurred any additional healthcare costs.
- Safety, all (S)AEs will be documented throughout the duration of the study.
研究者
PI
Scientific
Vrije Universiteit Brussel
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Comparison of two treatments (intrathecal baclofen pump and selective dorsal rhizotomy) for children with cerebral palsy who cannot walkCerebral Palsy2024-518822-33-01UZ Leuven27
尚未招募
不适用
Effect of morphine given during spinal anesthesia in participants undergoing laproscopic hyserectomy to see quality of recovery as the main outcomeCTRI/2025/11/096958BHAVYA PURI64
招募中
2 期
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal MetastasisNCT07263425The First Affiliated Hospital with Nanjing Medical University26
进行中(未招募)
1 期
Extracellular Vesicles for the Treatment of SyringomyeliaSyringomyeliaNCT07295067Xuanwu Hospital, Beijing18
招募中
3 期
Risk-benefit analysis of intrathecal morphine administration to patients undergoing surgical treatment of proximal femoral fracture (monocentric, single-blinded, randomized clinical study compared to standard treatment)2024-513996-42-00Fakultni Nemocnice Ostrava100
